Attention: This platform is in beta mode. Expect some changes and adjustments.

AI Market Mood: Stock Dashboard

AXL


Fundamental

Company: Dauch Corp
Sector: Consumer Cyclical
Industry: Auto Parts
Country: USA
Exchange: NYSE
Index: RUT
P/E: -
EPS (ttm): -0.17
Insider Own: 9.43%
Shs Outstand: 235.99M
Perf Week: 3.03%
Market Cap: 1.36B
Forward P/E: 5.86
EPS next Y: 0.99
Insider Trans: 0.16%
Shs Float: 213.74M
Perf Month: -1.03%
Enterprise Value: 3.41B
PEG: 0.15
EPS next Q: -0.17
Inst Own: 75.16%
Short Float: 12.97%
Perf Quarter: -10.94%
Income: -19.70M
P/S: 0.23
EPS this Y: -0.37%
Inst Trans: 15.49%
Short Ratio: 3.92
Perf Half Y: -4.93%
Sales: 5.84B
P/B: 1.07
EPS next Y Percentage: 86.86%
ROA: -0.34%
Short Interest: 27.73M
Perf YTD: -9.83%
Book/sh: 5.39
P/C: 0.62
EPS next 5Y: 39.50%
ROE: -3.28%
52W High: 9.25 -37.51%
Perf Year: 69.50%
Cash/sh: 9.35
P/FCF: 8.79
EPS past 3/5Y: - 49.29%
ROIC: -0.41%
52W Low: 3.00 92.67%
Perf 3Y: -18.93%
Dividend Est.: -
EV/EBITDA: 4.93
Sales past 3/5Y: 0.20% 4.38%
Gross Margin: 10.64%
Volatility W: 7.13%
Volatility M: 6.10%
Perf 5Y: -41.08%
Dividend TTM: -
EV/Sales: 0.58
EPS Y/Y TTM: -157.36%
Oper. Margin: 3.98%
ATR (14): 0.38
Perf 10Y: -60.27%
Dividend Ex-Date: Dec 04, 2008
Quick Ratio: 2.57
Sales Y/Y TTM: -4.71%
Profit Margin: -0.34%
RSI (14): 46.19
Recom: 2.00
Dividend Gr. 3/5Y: - -
Current Ratio: 2.95
EPS Q/Q: -448.13%
SMA20: 2.54%
Beta: 1.68
Target Price: 9.63
Payout: -
Debt/Eq: 6.64
Sales Q/Q: 0.22%
SMA50: -14.19%
Rel Volume: 0.38
Prev Close: 6.10
Employees: 18000
LT Debt/Eq: 6.58
Earnings: Feb 13 BMO
SMA200: -4.93%
Avg Volume: 7.08M
Price: 5.78
IPO: Jan 29, 1999
Option/Short: Yes / Yes
EPS/Sales Surpr.: 537.50% -0.93%
Trades:
Volume: 2,689,991
Change: -5.25%

Technical:


Latest News:

Pfizer denies offering Seoul double Paxlovid's supply price < Pharma < Article - KBR neutral
PFE

Summary: Pfizer Korea denied reports of requesting to double the supply price of its Covid-19 drug Paxlovid, ensuring ongoing discussions and cooperation with the government.

Full article
2024-08-21T10:08:52Z
Pfizer Will Charge $1,390 For 1 Course Of COVID Drug Paxlovid On Commercial Market somewhat bearish
PFE

Summary: Pfizer plans to price a course of the oral antiviral COVID-19 treatment Paxlovid at $1,390, significantly higher than what the government has paid, but various programs will assist with costs. Pfizer's sales forecast for the year has been reduced due to a drop in Paxlovid prescriptions and vaccine sales.

Full article
2024-05-21T21:14:46Z
UPDATE 4-Pfizer's COVID antiviral Paxlovid gains full US approval - Yahoo Sport Australia somewhat bullish
PFE

Summary: The U.S. FDA granted full approval to Pfizer's oral antiviral COVID-19 treatment Paxlovid, clearing the way for commercial sales at market rates, Pfizer sold around $18.9 billion of Paxlovid last year and forecasts sales of about $8 billion for 2023, ICER recommended a price range of $563 to $906 per treatment course for Paxlovid.

Full article
2024-05-19T23:56:18Z
American Axle & Manufacturing Holdings First Quarter 2024 Earnings: Beats Expectations somewhat bullish
AXL

Summary: American Axle & Manufacturing Holdings reported positive first quarter 2024 results with revenue up 7.6% and net income improving significantly. The company's revenues and earnings beat analyst expectations. Future revenue is expected to remain steady over the next 3 years.

Full article
2024-05-04T12:35:05Z
EPIC-SR: The negative paxlovid data Pfizer has been sitting on - First10EM somewhat bearish
PFE

Summary: EPIC-SR study reveals no benefit from paxlovid in treating COVID-19 patients, leading to the conclusion of not prescribing paxlovid in the vast majority of patients. The negative data from EPIC-SR contradicts Pfizer's rushed positive EPIC-HR study.

Full article
2024-04-22T10:17:48Z